To The Moon

UnitedHealth Group, the largest commercial health insurer in the United States, recently reported second-quarter earnings that surpassed Wall Street expectations, with adjusted earnings per share of $6.38, significantly above the analyst consensus range of $4.86 to $4.91. The stock surged over 6% following the announcement. However, this positive surprise hides a strategic dilemma facing the entire U.S. health insurance industry: what is the cost of restoring profitability?

For the second quarter, UnitedHealth generated revenue of $1120.3 billion, which was roughly flat year-over-year and quarter-over-quarter. Net profit reached $54.8 billion, or $6.04 per share, a substantial increase from $3.41 billion, or $3.74 per share, in the same period of 2025. The company also raised its full-year 2026 adjusted earnings per share guidance to between $19.50 and $20.00, up from the previous forecast of "greater than $18.25." This marks the second time UnitedHealth has lifted its full-year outlook this year, following a similar upward revision in April.

A newly released report, the 2026 Allianz Global Insurance Report, indicates that the global health insurance market grew by 12.3% in 2025, the highest rate since 2014, making it the most dynamic sector in the insurance industry. The U.S. market dominates this field, accounting for over 70% of global health insurance premiums, with a growth rate of 14.9%. In Asia, health insurance penetration remains below 1% in nearly all markets, suggesting substantial long-term growth potential.

Cost Control and AI Investment as Pillars of Profit Recovery

UnitedHealth CEO Stephen Hemsley attributed the strong results to the company's continuous efforts to "simplify operations, improve accessibility and the patient-provider experience, and leverage modern technology to create tangible improvements."

Numerically, the company's medical care ratio improved to 86.7% from 89.4% a year earlier. UnitedHealth also narrowed its full-year medical cost ratio guidance to 88.1% ± 25 basis points, down from the previous range of 88.8% ± 50 basis points, indicating a lower proportion of premium revenue being spent on medical claims.

The health services unit, Optum, posted second-quarter revenue of $65.7 billion and an operating profit of $4.0 billion, with its operating margin increasing by 160 basis points year-over-year. It served over 120 million people during the quarter. The operating margin for UnitedHealth's insurance business also improved to 4.6% from 2.4% in the same period of 2025. CFO Wayne DeVeydt emphasized the "very solid quality" of the earnings report, stating that the $19.50-$20.00 guidance range is a reasonable baseline for investors and that the company has the potential to perform even better.

Underpinning this cost control is a significant and increasing investment in technology. UnitedHealth plans to spend nearly $1.5 billion on AI-related technologies in 2026, with a similar budget expected for 2027. The company has already deployed over 1,000 AI applications across its business lines and employs over 2,000 AI engineers. Optum is actively promoting AI products to hospitals and other healthcare providers, including multi-payer claims solutions and operating room scheduling predictive analytics.

Hidden Concerns Behind the Numbers: Shrinking Scale for Profit

The other side of this impressive financial report reveals a difficult trade-off. In the second quarter, UnitedHealth served 48.5 million members, a decrease of 525,000 from the previous quarter. DeVeydt attributed the member loss primarily to affordability pressures from rising medical costs, forecasting a net loss of approximately 500,000 ACA marketplace members and 1.1 million Medicare Advantage members for the full year.

This is not the first time membership expectations have been lowered. In January, UnitedHealth predicted a total decline of 2.3 million to 2.8 million members across its commercial, Medicare Advantage, and Medicaid lines of business for 2026, with the ACA exchange business contracting by over 500,000 members. Dan Kueter, CEO of the commercial insurance unit, acknowledged that the ACA exchange business, after more than a decade, "has never been a significant contributor to profit."

During the first-quarter earnings call in April, UnitedHealth further increased its expected Medicare Advantage member loss from 1 million to between 1.3 million and 1.4 million. CEO Tim Noel described this as a "deliberate and proactive" repricing strategy rather than a passive response to competition.

It is notable that UnitedHealth's overall revenue remained stable despite member losses, largely due to price increases that offset the decline. However, DeVeydt acknowledged the limitations of this approach, stating, "Using price increases to compensate for member loss is not a good thing for the long-term health of the entire healthcare system."

This statement reflects the current predicament of the U.S. commercial health insurance industry. Amidst rising medical costs, insurers face a choice: either endure profit pressure to maintain scale or actively shrink their risk pool and exchange price for profit. The latter approach ultimately transfers the burden to consumers in the form of higher premiums and narrower coverage.

Comparing China and the U.S.: "Shrinking Scale and Raising Prices for Profit" vs. "Short-Term Pressure with Long-Term Optimism"

Turning to the domestic market, China's commercial health insurance industry faces a different but equally challenging growth dilemma.

According to data from the National Financial Regulatory Administration, China's commercial health insurance premium income was 997.3 billion yuan in 2025, with a growth rate of just 2.04%, significantly lower than the overall insurance industry's growth of 7.4%. In the first five months of this year, premium income was 552.1 billion yuan, with a slight recovery to a 3.9% growth rate. Life insurance companies' health premiums were 387.7 billion yuan, with growth nearly stagnant, while property and casualty insurers' health premiums were 164.4 billion yuan, growing 14.5%. This indicates a shift in growth momentum from traditional life insurance channels to property and casualty insurance channels.

The 2026 Allianz Global Insurance Report notes that unlike many global markets where health insurance is considered a niche product, it is a significant insurance category in China. The market structure is continuously optimizing, and its protection function is increasingly prominent. Driven by an aging population, rising medical costs, and pressure on the public healthcare system, the long-term growth potential for China's health insurance market is enormous.

The report forecasts that China's health insurance market will lead the world with an average annual growth rate of 8.1% over the next decade. This growth will be fueled by increasing healthcare demands from an aging population, a rising need for private coverage due to pressure on the public system, and growing health awareness and payment capacity among residents. The continued implementation of the "Healthy China 2030" strategy presents further opportunities for development.

UnitedHealth has demonstrated with its "shrinking scale for efficiency" earnings report that short-term profit recovery is achievable, but at the cost of a shrinking member base and rising premiums. Its own CFO admitted this path is "not good for the system's long-term health."

From an analytical perspective, China's commercial health insurance industry has not yet reached the point of deciding whether to reduce its scale. The real challenge lies in transitioning from "extensive scale expansion" to "high-quality and precise development." The key is to shift the industry's growth engine from one driven solely by critical illness insurance to one led by medical insurance with multi-product coordination, and to deeply integrate into the broader "healthcare-pharmaceutical-insurance" ecosystem.

While the anxieties of each market may differ in direction, they point to a common industry consensus: the traditional underwriting and claims model is increasingly insufficient to sustain long-term, stable growth. Technology investment is becoming a critical variable that major health insurance companies across almost all markets are betting on to find a breakthrough.

Leading domestic insurers have already initiated comprehensive AI-driven healthcare strategies. Recently, Ping An Insurance officially launched a "Disease-Specific AI Product Suite" targeting patients with serious illnesses like cancer. This suite includes products for disease prediction, disease-specific insurance, and a Peking University-backed AI disease management service. The prediction tools identify risk and detect high-risk groups early. The insurance products cover risks for populations with chronic diseases and cancer. The AI disease manager provides full-cycle cancer management, connecting doctors, hospitals, and rehabilitation resources to offer continuous services to severely ill clients, bridging disease risk detection, insurance protection, and professional medical services.

In the area of daily health management, Ping An's subsidiary, Ping An Good Doctor, announced that its upgraded "Ping An Smart Family Doctor" service now covers 90 million monthly active users. This service innovatively adopts an "AI + Human Doctor" dual-service model. The AI component can efficiently handle high-frequency needs like consultation triage, medication reminders, and medical report interpretation. For complex medical needs such as diagnosis and treatment of complicated conditions, long-term management of chronic diseases, and online prescriptions, the platform integrates human doctors for in-depth clinical decision-making. The service has moved beyond basic Q&A capabilities to substantively engage in clinical diagnostic and treatment support.

AI is a common solution chosen by both the U.S. and Chinese markets, but the underlying objectives are quite different. U.S. companies use technology to compress operational costs and hedge against structural premium pressures. In contrast, Chinese insurers use large medical models and full-process AI services to fill gaps in health management and expand coverage boundaries through supporting systems. For example, in April, Ping An's Medical Large Model 3.5 scored 57.27 points on the international authoritative HealthBench Hard platform, surpassing leading international models like OpenAI and ranking first globally.

Looking ahead, the value anchor of health insurance will eventually move beyond simple underwriting margins. For China's health insurance industry, the predicament of the overseas giant offers a critical warning: a profit model based solely on raising prices and shrinking the customer base is not sustainable. The core path for China's commercial health insurance to develop its own independent trajectory is to focus on domestic protection needs, persistently use technology to connect the entire chain of prevention, diagnosis, treatment, claims, and recovery, and to mitigate long-term risks while maintaining an inclusive nature.